Evidence map›Paper›PMID 38625644›Full record

ReviewClinical rheumatology2024

Rare combo: moyamoya and lupus in men.

Dilara Bulut Gökten, Murat Gökten, Çiğdem Deniz, Rıdvan Mercan

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Dilara Bulut GöktenDepartment of Rheumatology, Tekirdag Namik Kemal University, Tekirdag, Turkey. dilarabulutgokten@gmail.com.ORCID http://orcid.org/0000-0002-9226-7532
Murat GöktenDepartment of Neurosurgery, Tekirdag City Hospital, Tekirdag, Turkey.ORCID http://orcid.org/0000-0002-5659-4763
Çiğdem DenizDepartment of Neurology, Tekirdag Namik Kemal University, Tekirdag, Turkey.ORCID http://orcid.org/0000-0003-1325-4328
Rıdvan MercanDepartment of Rheumatology, Tekirdag Namik Kemal University, Tekirdag, Turkey.ORCID http://orcid.org/0000-0003-1537-2192
Tekirdağ Namık Kemal University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Moyamoya syndrome (MMS) is a rare, chronic, progressive cerebrovascular disorder characterized by stenosis at the apices of the intracranial internal carotid arteries, including the proximal anterior cerebral arteries and middle cerebral arteries. Cerebral angiography images are used for detection through measurement. Systemic lupus erythematosus (SLE) is an autoimmune disease that can cause multisystemic involvement. The coexistence of SLE and MMS has been rarely reported in the literature. A 46-year-old male patient with malar rash, Raynaud phenomenon presented to the hospital with a complaint of weakness in the left lower extremity, which began 3 days before the date of the visit. In the diffusion magnetic resonance imaging, multiple diffusion restrictions were observed in the right frontal region. The patient underwent MR angiography, revealing stenosis in the terminal and supraclinoid segments of the right internal carotid artery, which made us consider moyamoya disease. This patient, with a malar rash and Raynaud's, a positive antibody profile, was diagnosed as a male with SLE accompanied by MMS.

Indexed as

Lupus Erythematosus, SystemicMagnetic Resonance AngiographyMoyamoya DiseaseCarotid Artery, InternalCerebral AngiographyDiffusion Magnetic Resonance ImagingHumansMaleMiddle AgedRaynaud DiseaseLupusMale lupusMoyamoyaSLE

Identifiers

PMID38625644
OpenAlexW4394853196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.